Zentalis Pharmaceuticals (ZNTL) Return on Invested Capital (2022 - 2024)
Historic Return on Invested Capital for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to 0.63%.
- Zentalis Pharmaceuticals' Return on Invested Capital fell 600.0% to 0.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.63%, marking a year-over-year decrease of 600.0%. This contributed to the annual value of 0.49% for FY2024, which is 1900.0% up from last year.
- According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Return on Invested Capital is 0.63%, which was down 600.0% from 0.64% recorded in Q2 2025.
- Zentalis Pharmaceuticals' Return on Invested Capital's 5-year high stood at 0.53% during Q2 2024, with a 5-year trough of 0.67% in Q1 2025.
- Its 4-year average for Return on Invested Capital is 0.59%, with a median of 0.57% in 2023.
- As far as peak fluctuations go, Zentalis Pharmaceuticals' Return on Invested Capital plummeted by -1200bps in 2023, and later surged by 1000bps in 2024.
- Zentalis Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.53% in 2022, then dropped by -24bps to 0.65% in 2023, then increased by 15bps to 0.55% in 2024, then fell by -13bps to 0.63% in 2025.
- Its last three reported values are 0.63% in Q3 2025, 0.64% for Q2 2025, and 0.67% during Q1 2025.